Trader consensus on Polymarket reflects a narrow 54% implied probability for "No" on Eli Lilly licensing Peptron's SmartDepot drug delivery platform by October 7, 2026, driven by the absence of a commercial licensing or technology transfer agreement despite an ongoing evaluation extended from October 2024 to match the deadline. The initial non-exclusive research pact allowed Lilly internal testing of SmartDepot—Peptron's ultrasonic spray-drying tech for long-acting peptide formulations like GLP-1 agonists—but December 2025's extension without commercialization sparked Peptron stock declines and doubts amid Lilly's pivot toward oral obesity drugs and massive U.S. manufacturing investments. Balancing optimism from joint auto-injector collaboration hints, key swing factors include Q2 2026 earnings disclosures or regulatory filings that could signal deal progress, potentially tipping odds if positive data emerges from evaluations.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · ОновленоEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
НОВЕ
НОВЕ
Oct 7, 2026
НОВЕ
НОВЕ
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Trader consensus on Polymarket reflects a narrow 54% implied probability for "No" on Eli Lilly licensing Peptron's SmartDepot drug delivery platform by October 7, 2026, driven by the absence of a commercial licensing or technology transfer agreement despite an ongoing evaluation extended from October 2024 to match the deadline. The initial non-exclusive research pact allowed Lilly internal testing of SmartDepot—Peptron's ultrasonic spray-drying tech for long-acting peptide formulations like GLP-1 agonists—but December 2025's extension without commercialization sparked Peptron stock declines and doubts amid Lilly's pivot toward oral obesity drugs and massive U.S. manufacturing investments. Balancing optimism from joint auto-injector collaboration hints, key swing factors include Q2 2026 earnings disclosures or regulatory filings that could signal deal progress, potentially tipping odds if positive data emerges from evaluations.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Ринок відкрито: May 5, 2026, 8:02 PM ET
Обсяг
$8,217Дата завершення
Oct 7, 2026Ринок відкрито
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Trader consensus on Polymarket reflects a narrow 54% implied probability for "No" on Eli Lilly licensing Peptron's SmartDepot drug delivery platform by October 7, 2026, driven by the absence of a commercial licensing or technology transfer agreement despite an ongoing evaluation extended from October 2024 to match the deadline. The initial non-exclusive research pact allowed Lilly internal testing of SmartDepot—Peptron's ultrasonic spray-drying tech for long-acting peptide formulations like GLP-1 agonists—but December 2025's extension without commercialization sparked Peptron stock declines and doubts amid Lilly's pivot toward oral obesity drugs and massive U.S. manufacturing investments. Balancing optimism from joint auto-injector collaboration hints, key swing factors include Q2 2026 earnings disclosures or regulatory filings that could signal deal progress, potentially tipping odds if positive data emerges from evaluations.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Обсяг
$8,217Дата завершення
Oct 7, 2026Ринок відкрито
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Trader consensus on Polymarket reflects a narrow 54% implied probability for "No" on Eli Lilly licensing Peptron's SmartDepot drug delivery platform by October 7, 2026, driven by the absence of a commercial licensing or technology transfer agreement despite an ongoing evaluation extended from October 2024 to match the deadline. The initial non-exclusive research pact allowed Lilly internal testing of SmartDepot—Peptron's ultrasonic spray-drying tech for long-acting peptide formulations like GLP-1 agonists—but December 2025's extension without commercialization sparked Peptron stock declines and doubts amid Lilly's pivot toward oral obesity drugs and massive U.S. manufacturing investments. Balancing optimism from joint auto-injector collaboration hints, key swing factors include Q2 2026 earnings disclosures or regulatory filings that could signal deal progress, potentially tipping odds if positive data emerges from evaluations.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено
Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання